Contact

Category: Other Skin Conditions

Other Skin Conditions examines the veterinary and dermatological management of cutaneous acariasis, follicular demodicosis, scabietic mange, and inflammatory skin conditions responsive to avermectins.

Foundational Pillars
Pharmacological Framework
Clinical Directory
Frequently Asked Questions

Foundational Clinical Pillars

Core Reference

The Longevity of Ivermectin: A Detailed Chronicle of Clinical Use Across Five Decades

Comprehensive clinical directory of responsive cutaneous acariasis and skin pathologies.

Clinical Benchmark

How Long Has Ivermectin Been Around? A 50-Year History from 1974 to the Present

Evaluates facial dermatoses, perioral rash management, and topical acaricidal protocols.

Safety Standard

Where Did Ivermectin Come From? The Discovery of Streptomyces avermitilis and Satoshi Ōmura

Therapeutic skin scrapings, posology timelines, and mange eradication protocols.

Cutaneous Acariasis, Demodex Folliculorum Ecology & Skin Barrier Kinetics

Cutaneous parasitic infestations represent a major category of veterinary dermatological disease. Demodectic mange (caused by Demodex canis in dogs) results from the over-proliferation of microscopic commensal mites within hair follicles and sebaceous glands, often triggered by juvenile immune insufficiency or adult systemic immunosuppression.

In contrast, Sarcoptic mange (Sarcoptes scabiei) is a highly contagious, intensely pruritic dermatosis caused by female mites burrowing into the stratum corneum of the epidermis. Because sarcoptic mites elicit a hypersensitivity reaction, small numbers of mites can cause profound alopecia, lichenification, and secondary pyoderma across the ventral abdomen, elbows, and pinnae.

Dermatological ConditionPrimary Causal OrganismStandard Clinical Regimen
Canine Demodicosis (Generalized)Demodex canisDaily oral ivermectin (300-600 mcg/kg) or modern isoxazolines
Canine Sarcoptic MangeSarcoptes scabiei var. canisBi-weekly oral/SQ ivermectin (200-400 mcg/kg) for 4 weeks
Human Papulopustular RosaceaDemodex folliculorum & inflammationTopical 1% ivermectin cream once daily for 12 weeks
Cheyletiellosis (Fur Mites)Cheyletiella parasitovoraxBi-weekly systemic dosing or environmental acaricidal control

In human dermatology, topical 1% ivermectin cream is clinically indicated for papulopustular rosacea. The therapeutic mechanism is dual-action: it eradicates Demodex folliculorum and Demodex brevis mites while modulating local cutaneous inflammation by inhibiting neutrophil recruitment and inflammatory mediator synthesis.

Topic Directory & Methodologies

Canine Mange, Demodex & Sarcoptes

Topical Formulations & Rosacea Care

Advanced Formulations & Protocols

Frequently Asked Clinical Questions

How long does it take for ivermectin to clear demodectic mange?

Generalized demodectic mange typically requires 8 to 16 weeks of daily treatment, continuing until two consecutive monthly skin scrapings confirm zero living mites.

Is sarcoptic mange contagious to humans?

Yes. Sarcoptes scabiei is zoonotic; handling an infected dog can cause temporary, intensely itchy red papules on human arms and abdomen, though canine mites cannot complete their lifecycle on humans.

How does topical ivermectin cream improve rosacea?

It kills the microscopic Demodex mites residing in facial pores and suppresses the inflammatory cascade, reducing inflammatory papules and facial erythema.

Notice & Clinical Safe Harbor: This educational reference is maintained by the Veterinary Parasitology & Pharmacology Standards Desk for academic, informational, and clinical research purposes. Data models published veterinary pharmacology literature, statutory veterinary monographs, and established anthelmintic posology standards. This portal does not provide certified individual veterinary medical diagnosis, prescription services, or personalized treatment regimens. For clinical diagnoses, suspected parasitic toxicosis, and individualized dosing protocols, always consult an actively licensed veterinary practitioner in your jurisdiction.

AI Editorial Policy